Compare KBDC & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KBDC | IVA |
|---|---|---|
| Founded | 2021 | 2011 |
| Country | United States | France |
| Employees | N/A | 77 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 980.7M | 883.8M |
| IPO Year | 2018 | N/A |
| Metric | KBDC | IVA |
|---|---|---|
| Price | $14.32 | $4.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $15.50 | ★ $16.20 |
| AVG Volume (30 Days) | 201.9K | ★ 466.4K |
| Earning Date | 05-11-2026 | 03-30-2026 |
| Dividend Yield | ★ 13.16% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $193.84 | N/A |
| Revenue Next Year | $9.00 | $751.20 |
| P/E Ratio | $33.79 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.06 | $2.94 |
| 52 Week High | $16.28 | $7.98 |
| Indicator | KBDC | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 43.85 | 32.13 |
| Support Level | $14.02 | $3.77 |
| Resistance Level | $14.70 | $4.67 |
| Average True Range (ATR) | 0.29 | 0.32 |
| MACD | -0.07 | -0.12 |
| Stochastic Oscillator | 20.00 | 12.35 |
Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company, investing mainly in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation mainly through debt investments in middle-market companies.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.